Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, the genome editing company, today announced two key additions to the executive team - Gene Liau, Ph.D., as Senior Vice President, Gene Therapy and Bruce McCreedy, Ph.D., as Senior Vice President, Cell Therapy.

"We are excited to welcome Gene and Bruce to the Precision team," said Matthew Kane, Chief Executive Officer of Precision BioSciences. "Their proven leadership and breadth of experience will undoubtedly prove critical to our gene and cell therapy product development programs.

Suggested Articles

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.

Annexon has grabbed a healthy $100 million round to take its clinical work closer to the finishing line as it tees up shots on multiple targets.